Adient ADNT Gain (Loss) On Sale Of Equity Method Investment, And Other Than Temporary Impairment
Gain (Loss) On Sale Of Equity Method Investment, And Other Than Temporary Impairment at other companies
Other financials
Where this comes from
Reported directly by Adient in its filing.
Tagged under the XBRL concept adnt:GainLossOnSaleOfEquityMethodInvestmentAndOtherThanTemporaryImpairment.
The official record: Adient’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Adient's gain (loss) on sale of equity method investment, and other than temporary impairment.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Adient's gain (loss) on sale of equity method investment, and other than temporary impairment?
- Adient (ADNT) reported gain (loss) on sale of equity method investment, and other than temporary impairment of $0 in Q1 2026.
- What is the long-term trend for Adient's gain (loss) on sale of equity method investment, and other than temporary impairment?
- Over 3 years (2021 to 2024), Adient's gain (loss) on sale of equity method investment, and other than temporary impairment has grown at a -90.6% compound annual growth rate (CAGR), from $1.19B to $1M.
- What does gain (loss) on sale of equity method investment, and other than temporary impairment mean?
- This represents the realized gain or loss recognized upon the disposal of an investment accounted for under the equity method. It captures the difference between the proceeds received from the sale and the carrying value of the investment at the time of divestiture. This metric is critical for evaluating the success of the company's strategic portfolio management and capital allocation decisions regarding its joint ventures or minority stakes.